AnaptysBio (ANAB)

Executive Summary

AnaptysBio is a clinical-stage biotechnology company focused on developing best-in-class therapeutic antibodies for autoimmune and inflammatory diseases. The company employs a dual-strategy model, advancing its proprietary pipeline while also generating royalties from out-licensed assets. Its lead candidate, rosnilimab, is a novel anti-PD-1 agonist antibody designed to restore immune balance by inhibiting T-cell activation. Rosnilimab is being evaluated in Phase 2 trials for ulcerative colitis (UC) and rheumatoid arthritis (RA), with top-line data from the UC trial expected in mid-2026. The RA trial completed in May 2025, and data may be presented soon. AnaptysBio also has an early-stage pipeline including ANB032 (BTLA agonist) for atopic dermatitis, though this program was terminated in early 2025. The company plans to separate into two distinct publicly traded entities by the end of 2026, one focused on its proprietary pipeline and the other on royalty-generating assets. This separation is expected to unlock shareholder value. AnaptysBio faces challenges, including past clinical setbacks with etokimab and ANB032, but its unique mechanism of action and strategic restructuring provide potential upside. Key upcoming catalysts include rosnilimab data readouts, progress on the separation, and potential partnership opportunities. The company has a market cap of ~$1.65B and remains a high-risk, high-reward investment in the autoimmune space.

Upcoming Catalysts (preview)

• Q2 2026Rosnilimab Phase 2 Ulcerative Colitis Top-Line Data55% success
• H2 2026Completion of Corporate Separation into Two Entities80% success
• H2 2026Rosnilimab Phase 2 Rheumatoid Arthritis Data Presentation60% success